Atalanta Therapeutics secures $97m in Series B round to advance RNAi therapies

Atalanta’s ATL-101 is designed to target and silence the HTT gene for treating Huntington’s disease, a neurodegenerative condition. Credit: Milad Fakurian on Unsplash.